{"id":"NCT01252719","sponsor":"Melinta Therapeutics, Inc.","briefTitle":"Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)","officialTitle":"A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2012-10","completion":"2012-11-30","firstPosted":"2010-12-03","resultsPosted":"2022-08-01","lastUpdate":"2022-08-01"},"enrollment":968,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Wound Infection","Abscess","Systemic Inflammation","Cellulitis"],"interventions":[{"type":"DRUG","name":"Single-Dose IV Oritavancin Diphosphate","otherNames":[]},{"type":"DRUG","name":"IV Vancomycin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Single-Dose IV Oritavancin Diphosphate","type":"EXPERIMENTAL"},{"label":"IV Vancomycin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this Phase 3 trial was to evaluate the efficacy, safety, and tolerability of oritavancin in acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant staphylococcus aureus (MRSA), and to evaluate the potential economic benefit of oritavancin administered as a single 1200-milligram (mg) intravenous (IV) dose.","primaryOutcome":{"measure":"Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)","timeFrame":"48-72 hours after the initiation of study therapy","effectByArm":[{"arm":"Single-Dose 1200 mg Oritavancin","deltaMin":391,"sd":null},{"arm":"Vancomycin","deltaMin":378,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29358292","27370913","24897083"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":473},"commonTop":["Nausea","Headache","Pruritus","Infusion site reaction","Vomiting"]}}